Agenus Inc. (AGEN)
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
$132.67M
Dr. Garo H. Armen Ph.D.
441.00
Lexington, MA
Feb 04, 2000
-0.55
$-11.14
0.35
0.37
-139.99%
-0.59
-0.05
-0.54
0.84
0.37
-76.42%
122.08%
Similar stocks (10)
Viking Therapeutics, Inc.
VKTX
Madrigal Pharmaceuticals, Inc.
MDGL
TG Therapeutics, Inc.
TGTX
Edgewise Therapeutics, Inc.
EWTX
X4 Pharmaceuticals, Inc.
XFOR
PDS Biotechnology Corporation
PDSB
Leap Therapeutics, Inc.
LPTX
Marker Therapeutics, Inc.
MRKR
Pieris Pharmaceuticals, Inc.
PIRS
Galera Therapeutics, Inc.
GRTX
ETF Exposure (30)
Invesco DWA SmallCap Momentum ETF
DWAS
0.13%
Vanguard Strategic Small-Cap Equity Fund Investor Shares
VSTCX
0.13%
Vanguard Horizon Funds - Vanguard Strategic Equity Fund
VSEQX
0.1%
iShares Micro-Cap ETF
IWC
0.02686%
Vanguard Russell 2000 Value Index Fund
VTWV
0.01%
Schwab U.S. Small-Cap ETF
SCHA
0.0077409133%
iShares Russell 2000 Value ETF
IWN
0.00683%
iShares Russell 2000 ETF
IWM
0.00397%
WisdomTree BioRevolution Fund
WDNA
0.0024153%
ProShares Ultra Russell2000
UWM
0.001503924383510763%
iShares Russell 2000 Growth ETF
IWO
0.00108%
ProShares UltraPro Russell2000
URTY
7.408691489680818e-4%
Schwab U.S. Broad Market ETF
SCHB
6.678863e-4%
ProShares Hedge Replication ETF
HDG
6.283059664796254e-4%
iShares Core S&P Total U.S. Stock Market ETF
ITOT
1.7e-4%
iShares Russell 3000 ETF
IWV
1.1e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Health Care Index Fund
VHT
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Growth Index Fund
VTWG
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (10)
Viking Therapeutics, Inc.
VKTX
Madrigal Pharmaceuticals, Inc.
MDGL
TG Therapeutics, Inc.
TGTX
Edgewise Therapeutics, Inc.
EWTX
X4 Pharmaceuticals, Inc.
XFOR
PDS Biotechnology Corporation
PDSB
Leap Therapeutics, Inc.
LPTX
Marker Therapeutics, Inc.
MRKR
Pieris Pharmaceuticals, Inc.
PIRS
Galera Therapeutics, Inc.
GRTX
ETF Exposure (30)
Invesco DWA SmallCap Momentum ETF
DWAS
0.13%
Vanguard Strategic Small-Cap Equity Fund Investor Shares
VSTCX
0.13%
Vanguard Horizon Funds - Vanguard Strategic Equity Fund
VSEQX
0.1%
iShares Micro-Cap ETF
IWC
0.02686%
Vanguard Russell 2000 Value Index Fund
VTWV
0.01%
Schwab U.S. Small-Cap ETF
SCHA
0.0077409133%
iShares Russell 2000 Value ETF
IWN
0.00683%
iShares Russell 2000 ETF
IWM
0.00397%
WisdomTree BioRevolution Fund
WDNA
0.0024153%
ProShares Ultra Russell2000
UWM
0.001503924383510763%
iShares Russell 2000 Growth ETF
IWO
0.00108%
ProShares UltraPro Russell2000
URTY
7.408691489680818e-4%
Schwab U.S. Broad Market ETF
SCHB
6.678863e-4%
ProShares Hedge Replication ETF
HDG
6.283059664796254e-4%
iShares Core S&P Total U.S. Stock Market ETF
ITOT
1.7e-4%
iShares Russell 3000 ETF
IWV
1.1e-4%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Health Care Index Fund
VHT
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Growth Index Fund
VTWG
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Extended Market Index Fund
VXF
0%